PURPOSE: Recent studies indicate that ethyl pyruvate (EP) exerts anti-inflammatory properties; however, the effect of EP on ocular inflammation is not known. The efficacy of EP in endotoxin-induced uveitis (EIU) in rats was investigated. METHODS: EIU in Lewis rats was developed by the subcutaneous injection of lipopolysaccharide (LPS; 150 μg). EP (30 mg/kg body weight) or its carrier was injected intraperitoneally 1 hour before or 2 hours after lipopolysaccharide injection. Animals were killed after 3 and 24 hours followed by enucleation of eyes and collection of the aqueous humor (AqH). The number of infiltrating cells and levels of proteins in the AqH were determined. The rat cytokine/chemokine multiplex method was used to determine level of cytokines and chemokines in the AqH. TNF-α and phospho-nuclear factor kappa B (NF-κB) expression in ocular tissues were determined immunohistochemically. Human primary nonpigmented ciliary epithelial cells (HNPECs) were used to determine the in vitro efficacy of EP on lipopolysaccharide-induced inflammatory response. RESULTS: Compared to controls, AqH from the EIU rat eyes had a significantly higher number of infiltrating cells, total protein, and inflammatory cytokines/chemokines, and the treatment of EP prevented EIU-induced increases. In addition, EP also prevented the expression of TNF-α and activation of NF-κB in the ciliary bodies and retina of the eye. Moreover, in HNPECs, EP inhibited lipopolysaccharide-induced activation of NF-κB and expression of Cox-2, inducible nitric oxide synthase, and TNF-α. CONCLUSIONS: Our results indicate that EP prevents ocular inflammation in EIU, suggesting that the supplementation of EP could be a novel approach for the treatment of ocular inflammation, specifically uveitis.
PURPOSE: Recent studies indicate that ethyl pyruvate (EP) exerts anti-inflammatory properties; however, the effect of EP on ocular inflammation is not known. The efficacy of EP in endotoxin-induced uveitis (EIU) in rats was investigated. METHODS: EIU in Lewis rats was developed by the subcutaneous injection of lipopolysaccharide (LPS; 150 μg). EP (30 mg/kg body weight) or its carrier was injected intraperitoneally 1 hour before or 2 hours after lipopolysaccharide injection. Animals were killed after 3 and 24 hours followed by enucleation of eyes and collection of the aqueous humor (AqH). The number of infiltrating cells and levels of proteins in the AqH were determined. The rat cytokine/chemokine multiplex method was used to determine level of cytokines and chemokines in the AqH. TNF-α and phospho-nuclear factor kappa B (NF-κB) expression in ocular tissues were determined immunohistochemically. Human primary nonpigmented ciliary epithelial cells (HNPECs) were used to determine the in vitro efficacy of EP on lipopolysaccharide-induced inflammatory response. RESULTS: Compared to controls, AqH from the EIU rat eyes had a significantly higher number of infiltrating cells, total protein, and inflammatory cytokines/chemokines, and the treatment of EP prevented EIU-induced increases. In addition, EP also prevented the expression of TNF-α and activation of NF-κB in the ciliary bodies and retina of the eye. Moreover, in HNPECs, EP inhibited lipopolysaccharide-induced activation of NF-κB and expression of Cox-2, inducible nitric oxide synthase, and TNF-α. CONCLUSIONS: Our results indicate that EP prevents ocular inflammation in EIU, suggesting that the supplementation of EP could be a novel approach for the treatment of ocular inflammation, specifically uveitis.
Authors: M Santos Lacomba; C Marcos Martín; J M Gallardo Galera; M A Gómez Vidal; E Collantes Estévez; R Ramírez Chamond; M Omar Journal: Ophthalmic Res Date: 2001 Sep-Oct Impact factor: 2.892
Authors: Kan Koizumi; Vassiliki Poulaki; Sven Doehmen; Gerhard Welsandt; Sven Radetzky; Alexandra Lappas; Norbert Kociok; Bernd Kirchhof; Antonia M Joussen Journal: Invest Ophthalmol Vis Sci Date: 2003-05 Impact factor: 4.799
Authors: Luis Ulloa; Mahendar Ochani; Huan Yang; Mahira Tanovic; Daniel Halperin; Runkuan Yang; Christopher J Czura; Mitchell P Fink; Kevin J Tracey Journal: Proc Natl Acad Sci U S A Date: 2002-09-03 Impact factor: 11.205
Authors: Runkuan Yang; David J Gallo; Jeffrey J Baust; Takashi Uchiyama; Simon K Watkins; Russell L Delude; Mitchell P Fink Journal: Am J Physiol Gastrointest Liver Physiol Date: 2002-07 Impact factor: 4.052
Authors: P H Sande; D Dorfman; D C Fernandez; M Chianelli; A P Domínguez Rubio; A M Franchi; D M Silberman; R E Rosenstein; D A Sáenz Journal: Br J Pharmacol Date: 2014-12 Impact factor: 8.739
Authors: Divya Gupta; Yiqin Du; Jordan Piluek; Adam M Jakub; Kristine Ann Buela; Akshar Abbott; Joel S Schuman; Nirmala SundarRaj Journal: Invest Ophthalmol Vis Sci Date: 2012-09-25 Impact factor: 4.799
Authors: Nilesh M Kalariya; Mohammad Shoeb; Aramati B M Reddy; Rahul Sawhney; Kota V Ramana Journal: Int Immunopharmacol Date: 2013-07-25 Impact factor: 4.932
Authors: Nilesh M Kalariya; Mohammad Shoeb; Naseem H Ansari; Satish K Srivastava; Kota V Ramana Journal: Invest Ophthalmol Vis Sci Date: 2012-06-08 Impact factor: 4.799
Authors: Caroline de Freitas Zanon; Nathália Martins Sonehara; Ana Paula Girol; Cristiane Damas Gil; Sonia Maria Oliani Journal: Mol Vis Date: 2015-09-02 Impact factor: 2.367
Authors: Mohammad Shoeb; Min Zhang; Tianlin Xiao; Misha F Syed; Naseem H Ansari Journal: Invest Ophthalmol Vis Sci Date: 2018-01-01 Impact factor: 4.799
Authors: Yong Jie Qin; Kai On Chu; Yolanda Wong Ying Yip; Wai Ying Li; Ya Ping Yang; Kwok Ping Chan; Jia Lin Ren; Sun On Chan; Chi Pui Pang Journal: PLoS One Date: 2014-08-05 Impact factor: 3.240